Eli Lilly's Alzheimer's drug, Kisunla, faces NICE rejection in the UK due to concerns about cost-effectiveness and uncertainties about long-term benefits. The drug, like Leqembi, targets amyloid plaques but poses challenges with monitoring costs and accessibility.